Ads
related to: when should statins be discontinued
Search results
Results From The WOW.Com Content Network
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
“Cholesterol-lowering drugs save lives and prevent heart attacks and should be prescribed to all patients with coronary artery disease,” Dr. Nina Johnston, a study author and cardiologist at ...
However, due to its relatively severe adverse effects in comparison to other statins, its market use was discontinued. The strengths of the available cerivastatin medicine ranged from 0.2 - 0.8 mg, resulting in an actual dose of 1.9 - 13.1 μg/kg body weight for which rhabdomyolysis has been reported. [ 14 ]
Recent research (Nixon & Vendelø, 2016) shows that General Practitioners (GPs) who actively consider discontinuation, are reluctant to do so, as they experience that the safest decision is to continue prescriptions, rather than discontinue them. In part this is due to the ambiguity about the appropriateness of discontinuing medication.
Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [64] [65] [66] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [64]
Statins — a class of prescription drugs that slow down how much cholesterol the liver makes — can affect the LDL cholesterol. I’m not recommending anyone discontinue their statins without ...
The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...